Categories AlphaGraphs, Earnings, Health Care
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in revenues.
Total revenues increased to $2.37 billion in the first quarter from $2.10 billion in the corresponding period of 2022. For the full fiscal year, the management expects product revenues to be between $9.55 billion and $9.70 billion.
Meanwhile, adjusted earnings dropped to $3.05 per share in the March quarter from $3.52 per share in the prior-year period. Unadjusted profit was $699.8 million or $2.69 per share, compared to $762.1 million or $2.96 per share last year.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Important takeaways from Conagra Brands’ Q3 2025 report
Conagra Brands, Inc. (NYSE: CAG) has reported weaker-than-expected sales and profit for the February quarter as sales declined across business segments amid softer demand and persistent supply challenges. The maker
Main takeaways from Lamb Weston’s (LW) Q3 2025 earnings report
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) jumped 9% on Thursday after the company delivered better-than-expected results for the third quarter of 2025 and reaffirmed its outlook for the
Summary: Tesla (TSLA) reports Q1 2025 production, deliveries
Tesla Inc. (NASDAQ: TSLA) has announced results of vehicle production and deliveries for the first quarter of 2025. The company also provided data on the deployment of energy storage products
